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ABSTRACT
Mesial temporal lobe epilepsy (MTLE) is the most common form of partial epilepsy in young adults and also
the most frequent type of epilepsy reported in surgical series worldwide. Mesial temporal lobe sclerosis (MTS)
is the major underlying cause of MTLE, and it is present in 60-70% of patients with MTLE who undergo
surgery for treatment of medically refractory seizures. Pathogenetic mechanisms underlying this distinct
hippocampal pathology remains undetermined. Recent findings suggest a developmental malformation of
hippocampus (inherited or acquired) that in association with subsequent injury (e.g. trauma, infection,
complex febrile seizures) could develop ongoing seizures, resulting in the full-blown neuropathological features
of MTS. Genetic background, age and type of initial precipitating injury, and vulnerability related to
programmed cell death pathways are probable mechanisms involved in the development of MTS. Definitions
for medical intractability may vary among centers, but usually include failure to achieve seizure control with
two or more AEDs with adequate dosage and posology. The decision as to when one should perform surgery
in patients with MTLE is a relevant issue that needs more investigation. Recent evidence discussed in this
review indicates that longer duration of uncontrolled seizures is associated with an increased risk of
unsuccessful surgery.
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RESUMO
Epilepsia do lobo temporal mesial: uma visão atualizada
Epilepsia de lobo temporal mesial (ELTM) é a forma mais comum de epilepsia parcial em adultos jovens e
também a mais freqüente nas séries cirúrgicas mundiais. Esclerose mesial temporal (EMT) é a principal
causa de ELTM; presente em 60-70% dos pacientes submetidos ao tratamento cirúrgico para crises refratá-
rias. Os mecanismos patogênicos desta forma distinta de lesão hipocampal permanecem incertos. Achados
recentes sugerem uma malformação do desenvolvimento do hipocampo (hereditária ou adquirida) que em
associação com insultos subseqüentes (ex. trauma, infecção, crises febris complexas) poderiam provocar cri-
ses recorrentes, resultando nas características neuropatológicas da EMT. Substrato genético, idade e tipo de
insulto precipitante inicial e vulnerabilidade relacionada a mecanismos de morte celular programada são
prováveis mecanismos envolvidos no desenvolvimento da EMT. Definição de resistência ao tratamento clí-
nico pode variar entre centros especializados, mas geralmente inclui falha no controle de crises após dois ou
mais esquemas adequados de drogas antiepilépticas. A decisão de quando realizar um tratamento cirúrgico
em pacientes com ELTM é questão relevante e necessita ser investigada com maior profundidade. Evidência
recente discutida nesta revisão indica que duração prolongada de crises não controladas se associa a um
maior risco de falha no tratamento cirúrgico.
Unitermos: epilepsia de lobo temporal, crises, tratamento cirúrgico, esclerose hipocampal, esclerose mesial
temporal, fisiopatologia, ressonância magnética.
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Mesial temporal lobe epilepsy (MTLE) is the most
common form of partial epilepsy in adults(1), and it is
estimated that it represents about 40% of all epilepsies in
this age range. It can be sporadic, usually with positive
family history, or it can present with clear familial
recurrence(2).
Causes of MTLE include hippocampal sclerosis (HS),
small foreign tissue lesions such as hamartomas or glial
tumors, vascular and congenital malformations, and gliotic
lesions due to trauma or infections.
The terms “Ammon’s horn sclerosis”, “HS”, and
“mesial temporal sclerosis (MTS)” are often used inter-
changeably. The term “sclerosis” is originally a macroscopic
and descriptive one: it indicates shrinkage and induration
of the structure. Histologically, it implies selective neuronal
loss with secondary astroglial proliferation that affects
various sectors of the hippocampus to a different degree:
the most vulnerable to damage are the endfolium (sector
CA4), and sectors CA3 and CA1, while the granule cells
of the dentate gyrus, sector CA2 and subiculum are the
most resistant(3-5). This cell loss, if sufficiently pronounced,
will appear in MRI scans as a reduced volume or shrinkage
of the hippocampus, frequently associated with changes
in signal intensity. MTS is a histopathological term that
indicates neuronal loss and gliosis involving the hippo-
campus, and often also the amygdala, uncus and para-
hippocampal gyrus(3-5). Therefore, the term MTS is more
comprehensive than HS and perhaps would fit better when
discussing pathophysiologic mechanisms, MRI findings, or
clinical spectrum of the condition. HS would be more
appropriate when discussing histopathological findings
from specimens that include mainly, or sometimes, only
hippocampal tissue. This is the approach that will be used
in this review.
PATHOPHYSIOLOGY OF MTLE ASSOCIATED
WITH MTS
MTS is the major underlying cause of MTLE, and it is
present in 60-70% of patients with MTLE who undergo
surgery for treatment of medically refractory seizures.
Pathogenetic mechanisms underlying this distinct hippo-
campal pathology remains undetermined. Several studies
have shown a significant relationship between history of
prolonged febrile seizures (FS) in early childhood and
MTS. However, population based studies have not shown
a significant relationship between FS early in life and
subsequent MTLE(6;7). The interpretation of these obser-
vations remains controversial(8). One possibility is that
early FS damages the hippocampus and is therefore a cau-
se of MTS. Alternatively; a child may have prolonged FS
because the hippocampus was previously damaged due
to a prenatal/perinatal insult or genetic predisposition.
Recent studies have shown that prolonged and focal FS
can produce acute hippocampal injury that evolves to
hippocampal atrophy and that complex FS can actually
originate in the temporal lobes in some children(9). MRI
studies in familial MTLE demonstrated magnetic reso-
nance imaging (MRI) evidence of MTS in patients with
benign epilepsy and seizure remission, or even individuals
who had a single seizure, suggesting that the relationship
between MTS and severity of TLE might be more complex
than previously suspected(1,2,8,10,11). MTS most likely has
different causes and results from complex interactions
among genetic and environmental factors. Recent mo-
lecular neuropathological studies focusing on develop-
mental aspects of hippocampal organization revealed two
intriguing findings in HS specimens of MTLE patients who
underwent surgery: (i) The persistence of Cajal-Retzius
cells in HS patients points towards an early insult and an
altered Reelin signaling pathway and (ii) increased
neurogenesis in and abnormal architectural organization
of the dentate granule cell layer can be observed in young
patients with early hippocampal seizure onset. These
findings suggest a developmental malformation of hippo-
campus (inherited or acquired) that in association with
subsequent injury (e.g. trauma, infection, FS) could
develop ongoing seizures, resulting in the full-blown
neuropathological features of HS(12). Genetic back-
ground(2), age and type of initial precipitating injury(13,14),
vulnerability related to programmed cell death pathways(15)
are probable mechanisms involved in the development
of HS.
DIAGNOSTIC PRINCIPLES
The first habitual seizures usually occur in late
childhood or early adolescence. The initial ictal event may
be a generalized convulsion or a complex partial seizure.
Complex partial seizures are usually preceded by an aura
(simple partial seizure); typically involving rising epigastric
sensation associated with an emotional disturbance such
as fear. Other psychic and autonomic symptoms are also
seen, and some patients can have olfactory or gustatory
sensations. Auras typically occur in isolation, as well as in
association with complex partial seizures, and patients may
recall occasional auras years before they experienced the
first habitual complex partial seizure. The complex partial
seizure commonly begins with a motionless stare and
oroalimentary automatisms (eg, lip smacking, chewing),
during which the patient may be unresponsive. Gestural
and reactive automatisms, that can be ictal or postictal,
are also common. When posturing of one extremity occurs,
it is contralateral to the side of ictal onset. Seizures
typically last about one minute or less. There are no
definitive characteristics that distinguish complex partial
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seizures reflecting MTLE from complex partial seizures
generated in the anterior portion of the temporal lobe or
due to mesial temporal lesions other than MTS.
Neurological examination is usually normal with the
exception of memory deficits. Interictal electroencepha-
logram (EEG) findings in patients with MTLE typically
include unilateral or bilaterally-independent mesial tem-
poral spikes, best seen with basal (sphenoidal, inferior tem-
poral) derivations. Ictal EEG recordings usually reveal ictal
onset consisting of rhythmic 5 to 7 Hz activity in one mid-
inferomesial temporal region, but there may be variations
in this pattern. High-resolution MRI often demonstrates
unilateral or bilateral hippocampal atrophy associated with
hypertintense T2 signal in one or both hippocampi
sometimes extending to amygdala or other medial tempo-
ral structures. These findings are highly specific for MTS.
The same temporal lobe is usually hypometabolic on
interictal FDG-PET (Positron emission tomography). It
has been widely accepted, based on large series of surgical
patients, that there is a strong correlation between MTS
and the severity of the epilepsy. In addition, MTS
identified by MRI has been associated with poor control
of seizures by antiepileptic medication.  However, the
findings of MRI abnormalities in patients with good
outcome or seizure remission, indicates that MTS is found
not only in patients with medically refractory mesial
TLE(1,2,8,10,16). Evidence for this has already been hinted at
in the literature, including descriptions of sporadic patients
with MTS(17). Furthermore, there are upcoming MRI
evidence of MTS acquired in adulthood not necessarily
associated with a poor seizure control(11).
THERAPEUTIC PRINCIPLES
Carbamazepine and/or phenytoin as monotherapy are
the appropriate medications for management of MTLE.
Higher serum levels than those used for generalized
seizures may be necessary, and medication should be
increased until seizures stop or unacceptable side effects
occur. Oxcarbazepine has an efficacy similar to that of
carbamazepine, but patients may tolerate higher dosages
with fewer side effects, and in some individuals this can
make a difference in seizure control.  Valproate, topira-
mate, or lamotrigine are of benefit when carbamazepine
and phenytoin fail. Combination of drugs are usually
ineffective, with the exception of clobazam associated with
carbamazepine or phenytoin(18). When seizures become
refractory to medical treatment, they are unlikely to
remit spontaneously. With long duration of uncontrolled
seizures, increasing memory problems and other behavioral
disturbances are usually reported. This sequence of events
suggests that MTLE may be a progressive epileptic
disorder(11). Because of the psychosocial consequences of
disabling epilepsy in adolescence and early adulthood,
patients who may have MTLE should be referred to
epilepsy centers as soon as it is apparent that control
cannot be achieved with first-line medications. These
patients are excellent candidates for surgical treatment,
with a great chance (80-90%) of becoming free of disabling
seizures. Psychosocial intervention is also important in
the management of many patients with mesial TLE,
and is particularly important for rehabilitation following
successful surgery.
NATURAL HISTORY OF EPILEPSY AND
RELEVANCE OF EARLY SURGICAL
TREATMENT FOR EPILEPSY
Information on the natural history of the epilepsies is
confounded by almost inevitable therapeutic intervention
that most likely alters the clinical course. However, in some
situations the timing of this therapeutic intervention
itself provides important information. A major study on
prognosis in epilepsy listed the following among the risk
factors for an adverse outcome: a young age at onset, more
seizures prior to the first visit to a physician, and a longer
duration of illness(19). Most subsequent studies have
confirmed these findings(20). It can be argued, however,
that the poor prognosis for patients whose seizures take
longer to control, or who have more frequent seizures, is
due to more severe epilepsy initially, rather than the
occurrence of seizures per se(21). Prognosis in these studies
also depended on other features such as neurological
deficits and underlying etiology(22), that clearly reflect the
severity of the epileptogenic process from start. Conse-
quently, these data do not directly address the issue of the
progressive nature of epilepsy(11).
For the approximately 20%-30% of patients with
epilepsy that are not well controlled with antiepileptic
drugs (AEDs), surgery is worth considering when the
patient’s seizures arise from an area that can be surgically
treated without causing unacceptable neurological de-
ficits(23).
Definitions for medical intractability may vary among
centers, but usually include failure to achieve seizure
control with two or more AEDs with adequate dosage and
posology. The decision as to when one should perform
surgery may be more difficult and controversial, unless in
extreme situations, such as in the presence of a growing
tumor or in children with catastrophic epilepsies that are
amenable to surgical resection. In a recent publication,
Yoon et al.(24) showed that duration of preoperative epilepsy
of more than 20 years and age at surgery over 30 years were
associated with an increased risk of recurrence of seizures.
Unfortunately, only few patients had surgery within the first
10 years of their epilepsy which make it difficult to evaluate
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if earlier intervention would have offered these patients
better prognosis for seizure freedom(25). Traditionally,
physicians, including many neurologists, have considered
epilepsy surgery the last treatment option for patients with
partial epilepsies. The average duration of surgically
treatable epilepsy among young and middle-aged adults
referred for epilepsy surgery at major adult epilepsy centers
is about 20 years(25,26). Age at surgery per se may not be the
only factor to influence prognosis. For example, Berg et
al.(27) showed that patients with early childhood seizure
onset have long latencies before developing refractory
epilepsy, whereas older patients have shorter latencies. A
better definition of when patients with partial epilepsy
become refractory is of foremost importance for more
‘aggressive’ medical treatment or earlier surgical inter-
vention in a given patient. This is particularly important
in the context of MTLE.
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